share_log

iBio Inc | 3: Initial statement of beneficial ownership of securities-Officer Banjak Marc

iBio Inc | 3: Initial statement of beneficial ownership of securities-Officer Banjak Marc

iBio Inc | 3:首次持股聲明-高管 Banjak Marc
美股SEC公告 ·  08/14 17:26

Moomoo AI 已提取核心訊息

Marc Banjak, Chief Legal Officer of iBio Inc, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on August 14, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Banjak's direct ownership of non-derivative and derivative securities in the company. The non-derivative securities include 1,875 shares of common stock represented by restricted stock units (RSUs) that vested quarterly over 12 months, with the final tranche vesting on March 31, 2024. Additionally, the filing outlines multiple stock options with varying vesting schedules and exercise prices, including options for 800 shares at $170.4, 600 shares at $141.2, 3,000 shares at $6.92, 29,000 shares at $1.72, and 55,000 shares at $1.88. These options have exercise periods ranging from 2022 to 2034 and are contingent upon Banjak's continued employment with iBio Inc.
Marc Banjak, Chief Legal Officer of iBio Inc, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on August 14, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Banjak's direct ownership of non-derivative and derivative securities in the company. The non-derivative securities include 1,875 shares of common stock represented by restricted stock units (RSUs) that vested quarterly over 12 months, with the final tranche vesting on March 31, 2024. Additionally, the filing outlines multiple stock options with varying vesting schedules and exercise prices, including options for 800 shares at $170.4, 600 shares at $141.2, 3,000 shares at $6.92, 29,000 shares at $1.72, and 55,000 shares at $1.88. These options have exercise periods ranging from 2022 to 2034 and are contingent upon Banjak's continued employment with iBio Inc.
iBio inc的首席法律官Marc Banjak於2024年8月14日向SEC提交了有關證券的初始有益所有權報告。根據證券交易法案第16(a)條的規定,該報告詳細說明了Banjak在公司中直接擁有的非衍生和衍生證券的所有權。其中,非衍生證券包括由限制性股票單元(RSU)代表的1,875股普通股,該股票將在12個月內按季度分期歸屬,最後一批於2024年3月31日歸屬。此外,該報告還概述了多個股票期權,包括條件各異的行權價格和歸屬計劃,其中包括800股,行權價格爲170.4美元,600股,行權價格爲141.2美元,3,000股,行權價格爲6.92美元,29,000股,行權價格爲1.72美元,以及55,000股,行權價格爲1.88美元。這些期權的行權期限從2022年到2034年不等,並取決於Banjak繼續在iBio inc工作。
iBio inc的首席法律官Marc Banjak於2024年8月14日向SEC提交了有關證券的初始有益所有權報告。根據證券交易法案第16(a)條的規定,該報告詳細說明了Banjak在公司中直接擁有的非衍生和衍生證券的所有權。其中,非衍生證券包括由限制性股票單元(RSU)代表的1,875股普通股,該股票將在12個月內按季度分期歸屬,最後一批於2024年3月31日歸屬。此外,該報告還概述了多個股票期權,包括條件各異的行權價格和歸屬計劃,其中包括800股,行權價格爲170.4美元,600股,行權價格爲141.2美元,3,000股,行權價格爲6.92美元,29,000股,行權價格爲1.72美元,以及55,000股,行權價格爲1.88美元。這些期權的行權期限從2022年到2034年不等,並取決於Banjak繼續在iBio inc工作。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息